BILIARY TRACT CANCER
Clinical trials for BILIARY TRACT CANCER explained in plain language.
Never miss a new study
Get alerted when new BILIARY TRACT CANCER trials appear
Sign up with your email to follow new studies for BILIARY TRACT CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Cancer drug combo trial halted early: what we learned
Disease control TerminatedThis study tested a combination of two drugs, niraparib and dostarlimab, in adults with advanced solid tumors that either had DNA repair problems or were sensitive to platinum chemotherapy. The goal was to see how many patients' tumors shrank or disappeared. The trial was stopped…
Matched conditions: BILIARY TRACT CANCER
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated May 26, 2026 08:31 UTC
-
New cancer pill shows promise but trial ends early
Disease control TerminatedThis study tested a new drug, BI 907828, in adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplified, TP53 normal). Participants took a pill every three weeks. The trial was stopped early, but researchers were c…
Matched conditions: BILIARY TRACT CANCER
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 26, 2026 08:30 UTC
-
New drug combo tested for tough cancers
Disease control TerminatedThis early-phase study tested a new drug called SO-C101, alone or with pembrolizumab, in 115 people with advanced solid tumors (like lung, kidney, or skin cancer) that stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study …
Matched conditions: BILIARY TRACT CANCER
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Bile duct cancer combo trial halted early
Disease control TerminatedThis study tested a new drug combination (GEN-001 plus pembrolizumab) in 10 adults with advanced bile duct cancer that had stopped responding to standard treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was terminated early, so result…
Matched conditions: BILIARY TRACT CANCER
Phase: PHASE2 • Sponsor: Genome & Company • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Promising combo for bile duct cancer trial halted early
Disease control TerminatedThis study tested whether adding the experimental drug CPI-613 to standard chemotherapy (gemcitabine and cisplatin) could help people with advanced biliary tract cancer that cannot be removed by surgery. About 75 participants were planned, but the trial was stopped early. The goa…
Matched conditions: BILIARY TRACT CANCER
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Blood test holds promise for early liver cancer detection
Diagnosis TerminatedThis study looked at whether tiny bits of genetic material (extracellular RNA) found in the blood can help doctors diagnose liver cancer or other liver diseases. Researchers planned to enroll about 1,865 people with liver cancer, bile duct cancer, cirrhosis, or chronic liver dise…
Matched conditions: BILIARY TRACT CANCER
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated May 11, 2026 20:52 UTC